The Results and Key Takeaways From GOG0213

March 28, 2015

Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213.

Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213. This phase III trial compared carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary, and fallopian tube cancer.

<<<

View more from SGO 2015